CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 91 enrolled
Drug / intervention
STC-19 scoreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04371471
NCT04371471N/ACompleted
CompareCT.gov

On-admission Multifactorial Evaluation of Inflammation as Prognostic Marker of Death in Patients Diagnosed With Coronavirus Infectious Disease (COVID-19) Syndrome

Groupe Hospitalier de la Rochelle Ré Aunis·observational·Posted May 1, 2020·Updated Jul 19, 2022

In Brief

An observational study evaluating STC-19 score for SARS-CoV-2 Acute Respiratory Disease and Covid19. Completed, enrolled 91 participants across 1 site.

Detailed Summary

During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality. When patients with suspected or confirmed COVID-19 are admitted to hospital, whether or not they are symptomatic, there is currently no method to predict who will progress to complications requiring the use of intensive measures in 24-48 hours.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Acute Respiratory Disease, Covid19
CountriesFrance
CollaboratorsNumaHealth International

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 1, 2020
Enrollment StartMar 1, 2020
Primary CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.2 years ago

Interventions

STC-19 scoreother

Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)